Viridian Therapeutics’ (VRDN) Equal Weight Rating Reiterated at Wells Fargo & Company

Wells Fargo & Company reaffirmed their equal weight rating on shares of Viridian Therapeutics (NASDAQ:VRDN) in a report released on Thursday morning, MarketBeat.com reports. They currently have a $27.00 target price on the stock, down from their previous target price of $37.00.

Other equities analysts also recently issued research reports about the stock. The Goldman Sachs Group upped their price objective on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, September 12th. Royal Bank of Canada upped their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Tuesday, December 17th. BTIG Research lifted their price objective on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, September 26th. TD Cowen began coverage on Viridian Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $35.70.

Viridian Therapeutics Price Performance

NASDAQ VRDN opened at $19.03 on Thursday. The firm’s fifty day simple moving average is $21.72 and its two-hundred day simple moving average is $18.11. The firm has a market capitalization of $1.51 billion, a P/E ratio of -4.42 and a beta of 1.04. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics has a 12-month low of $11.40 and a 12-month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.08 million. Analysts forecast that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Insider Buying and Selling at Viridian Therapeutics

In other news, COO Thomas W. Beetham bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average cost of $23.41 per share, for a total transaction of $117,050.00. Following the purchase, the chief operating officer now directly owns 6,000 shares in the company, valued at approximately $140,460. This trade represents a 500.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Stephen F. Mahoney purchased 21,400 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the transaction, the chief executive officer now owns 21,400 shares of the company’s stock, valued at $499,262. This trade represents a ? increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.65% of the company’s stock.

Hedge Funds Weigh In On Viridian Therapeutics

Large investors have recently bought and sold shares of the business. Quest Partners LLC grew its holdings in Viridian Therapeutics by 344.0% in the second quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock valued at $79,000 after purchasing an additional 4,692 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Viridian Therapeutics during the 3rd quarter valued at approximately $149,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Viridian Therapeutics by 24.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after acquiring an additional 2,359 shares during the period. AlphaCentric Advisors LLC increased its holdings in Viridian Therapeutics by 108.3% in the 2nd quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock worth $163,000 after acquiring an additional 6,500 shares in the last quarter. Finally, Arizona State Retirement System raised its position in Viridian Therapeutics by 14.7% during the second quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock worth $171,000 after acquiring an additional 1,688 shares during the period.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.